Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complications.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analysis
PubMed 22343494 · doi:10.1038/aja.2011.109
What was done
Narrative review summarizing published literature on the adverse effects of androgen deprivation therapy (ADT) in men with prostate cancer, focusing specifically on metabolic and cardiovascular complications.
What was found
The abstract reports no numerical data, effect sizes, or statistical metrics. It describes established adverse effects of ADT-induced hypogonadism, including reduced muscle mass and strength, increased fat mass, sexual dysfunction, vasomotor symptoms, impaired quality of life, anemia, bone loss, and newer recognized risks of insulin resistance, diabetes, and cardiovascular disease.
Why it matters
Because many patients with prostate cancer die from non-malignant causes, identifying and addressing ADT-associated cardiovascular and metabolic risks is critical for optimizing overall survival and care.
Limits
The abstract provides no quantitative data, sample size, or search methodology. As a narrative review, it lacks systematic study selection, risk of bias assessment, and quantitative synthesis.
Cited by
- supports Androgen deprivation therapy in prostate cancer patients typically causes increased fat mass, loss of muscle mass, elevated cardiovascular disease risk, and insulin resistance or diabetes.